-+ 0.00%
-+ 0.00%
-+ 0.00%
SOPHiA GENETICS partners with AstraZeneca on two oncology companion diagnostics
Share
Listen to the news
SOPHiA GENETICS partners with AstraZeneca on two oncology companion diagnostics
  • SOPHiA GENETICS entered a multi-year global collaboration with AstraZeneca to develop, validate, deploy two companion diagnostics for precision oncology therapies.
  • Deal targets decentralized companion diagnostics, aiming to support AstraZeneca launches across laboratories regardless of geography.
  • Solid Tumor application to be developed into a decentralized companion diagnostic; Hematological Oncology application to be developed, validated for blood cancer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sophia Genetics SA published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608040615PR_NEWS_USPR_____NE18213) on August 04, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending